Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease

Fonarow, G.C., van Hout, B. orcid.org/0000-0001-9698-6094, Villa, G. et al. (2 more authors) (2019) Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease. JAMA Cardiology. ISSN 2380-6583

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2019 American Medical Association.
Dates:
  • Accepted: 10 April 2019
  • Published (online): 5 June 2019
  • Published: 5 June 2019
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Depositing User: Symplectic Sheffield
Date Deposited: 25 Jun 2019 13:18
Last Modified: 25 Jun 2019 13:18
Status: Published online
Publisher: American Medical Association
Refereed: Yes
Identification Number: https://doi.org/10.1001/jamacardio.2019.1647
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics